Additionally, AK104 (a PD-1/CTLA-4 BSAB) treatment in patients with metastatic NPC who have failed second-line chemotherapy has demonstrated favorable antitumor activity (ORR, 30%; DCR, 70%), particularly in PD-L1-positive patients (ORR, 57.1%). The gene discussed is CTLA4; the disease is nasopharyngeal carcinoma.